On May 16, I had the opportunity to attend a patient and family conference in Tampa, Florida, with the Aplastic Anemia and MDS International Foundation, and I walked away with something much bigger than the usual information and resources. I left with connection, understanding, and a renewed sense of…
Treatment with C5 inhibitors, a class of approved medications for paroxysmal nocturnal hemoglobinuria (PNH) that block activation of the complement cascade — a part of the immune system that is overactive in the disease — was associated with partial recovery of certain immune cell populations, a study in China…
Treatment with Ultomiris (ravulizumab) safely helps maintain or achieve disease control in people with paroxysmal nocturnal hemoglobinuria (PNH), according to a real-world study involving more than 200 adults. Among that group, people who switched from the older therapy, Soliris (eculizumab), to…
Discussion
Note: This column describes the author’s experiences with Fabhalta (iptacopan). Not everyone will have the same response to treatment. Consult your doctor before starting or stopping a therapy. There’s something powerful about being able to say, “This is getting better.” After the uncertainty that came with my recent medication change for…
Get regular updates delivered to your inbox.
